Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514408000 The five-membered hetero ring consists of one nitrogen and four carbons 965
514385000 1,3-diazoles 601
514365000 1,3-thiazoles (including hydrogenated) 448
514403000 1,2-diazoles 271
514361000 Plural ring nitrogens and a single chalcogen in the hetero ring 213
514381000 Tetrazoles (including hydrogenated) 140
514383000 1,2,4-triazoles (including hydrogenated) 129
514374000 1,3-oxazoles (including hydrogenated) 120
514378000 1,2-oxazoles (including hydrogenated) 93
514372000 1,2-thiazoles (including hydrogenated) 72
514360000 Plural ring chalcogens in the hetero ring 6
Entries
DocumentTitleDate
20090275619Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors - The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.11-05-2009
20100130565THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel thioamide derivatives of formula (I) and formula (Ia):05-27-2010
20130045998PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE - The present invention refers to an improved method for the preparation of compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylic acid substantially free of its 3H-I isomer. The invention also refers to the use of said intermediate for the preparation of Rufinamide and for obtaining a new polymorphic form of Rufinamide, designed as Form R-5. The invention also refers to said new polymorph of Rufinamide, and to the composition containing it and its use as medicament. The new polymorph of Rufinamide shows good stability and appropriate physico-chemical properties for its manipulation on industrial scale. Polymorph Form R-5 will be suitable to use as pharmaceutical for the treatment of convulsions, especially for the treatment of epilepsy.02-21-2013
20090306153SYNTHESIS AND USE OF NOVEL INHIBITORS AND INACTIVATORS OF PROTEIN ARGININE DEIMINASES - In one embodiment of the present disclosure, an inactivator of protein arginine deiminase 4 is disclosed. The inactivator includes: (I) and x includes F; Cl, and H, y includes OH and NH12-10-2009
20090054501AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS - This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII.02-26-2009
20090105314Pharmaceutical Agent - The present invention provides an agent for the prophylaxis or treatment of complications after coronary-artery bypass surgery or cardiac diseases, autoimmune diseases, central nervous system diseases, inflammatory diseases, sepsis, severe sepsis or septic shock in a patient who undergoes coronary-artery bypass surgery, which comprises a compound represented by the formula (I):04-23-2009
20110172278COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.07-14-2011
20100016381STABLE EMULSION COMPOSITION - The present invention provides an emulsion composition comprising (A) a compound stable in an acidic range, and (B) a buffer, wherein the pH is adjusted from about 3.7 to about 5.5.01-21-2010
20090163559Estrogen receptor modulators - The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, age-related mild cognitive impairment, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, irritable bowel syndrome, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.06-25-2009
20110230527CASPASE INHIBITORS AND USES THEREOF - This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6.09-22-2011
20090239913Process for the treatment and prevention of diseases caused by fungi - The subject invention is directed to the treatment of infections caused by fungi which are resistant to standard antifungal drugs such as fluconazole. The treatment method involves administering to the sufferer an effective amount of an agent that suppresses the activity of the fungal (H+)-ATPase pump (Pma1p). Such agents may take the form of: a) 2-phenyl-1,2-benzisoselenazol-3(2H)-one, commonly referred to as ebselen and depicted by Formula I, or b) 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide, commonly referred to as ebselen se-oxide and depicted by Formula II, or pharmaceutically acceptable salts thereof. Opportunistic fungal infections include those which are systemic and those which are superficial and are caused by species of fungi belonging to the genus 09-24-2009
20090253756Indole Amide Derivatives as EP4 Receptor Antagonists - The invention is directed to indole amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.10-08-2009
20100227899Process for the treatment of bacterial infections using 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide - The subject invention demonstrates a novel antibacterial activity for 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide, commonly referred to as ebselen se-oxide, and is directed to the treatment of bacterial infections by administration of an effective amount of said compound. Bacterial infections include those infections which are either systemic or superficial in nature. The treatment is intended for a variety of animals, such as premature neonates to adult humans. Administration of ebselen se-oxide to treat superficial bacterial infections may be performed by a topical application, such as via an ointment, a spray, a cream, a mouth wash, an eye drop solution, an ear drop solution, a soap, a gel, or a lotion. In addition, an antibacterial capsule can be administered orally or intravaginally. Administration of ebselen se-oxide to treat systemic bacterial infections may be performed by an intravenous route, a rectal route, an intranasal route, an oral route, an intramuscular route, or by inhalation. Administration of said compound may also be achieved via aerosol, which can be generated by a nebulizer. Ebselen se-oxide may be administered alone, or with a carrier such as dimethylsulfoxide (DMSO), an alcohol, or other suitable carrier. The effective daily amount of ebselen se-oxide is from about 1 μg/kg to 10 mg/kg of body weight.09-09-2010
20100240715Apoptosis promoters - Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.09-23-2010
20090326015COMPOUNDS WITH EMBEDDED BENZOPYRAN MOTIF FOR CORE STRUCTURES AND PREPARATION METHOD THEREOF - The present invention relates to a compound having benzopyran core, a preparation method of the derivatives by liquid phase synthesis and solid phase synthesis through diversity-oriented synthesis, and an anticancer agent comprising the compound that exhibit excellent cytotoxicity against cancer cells.12-31-2009
20090069390DEUTERIUM-ENRICHED RUFINAMIDE - The present application describes deuterium-enriched rufinamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-12-2009
20110060017NOVEL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetyl-choline receptors. Due to their pharmacological profile, the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.03-10-2011
20100120873PROPHYLACTIC OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION - An object of the present invention is to find a novel medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent inhibitory effect on neovascularization in the choroid and also has a protective effect on retinal pigment epithelial cell damage, and therefore is useful as a prophylactic or therapeutic agent for age-related macular degeneration.05-13-2010
20110028522FULLERENE THERAPIES FOR INFLAMMATION - Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.02-03-2011
20110201657AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS - The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.08-18-2011
20110201656NOVEL DIPHENYL 1,2,3-TRIAZOLE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to novel diphenyl 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.08-18-2011
20100029726CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA - The present invention provides compounds of formula I:02-04-2010
20100029725RESISTANCE MANAGEMENT STRATEGIES - Insect refuge strategies are described for the management of insect resistance development. The present invention relates generally to the control of pests that cause damage to crop plants, and in particular to corn plants, by their feeding activities directed to root damage, and more particularly to the control of such plant pests by exposing target pests to seeds or mixtures of seeds having multiple different modes of action. The first one or more transgenes and the second one or more transgenes are each, respectively, insecticidal to the same target insect but have different modes of action, and bind either semi-competitively or non-competitively to different binding sites in the target pest. In addition, the treatment of such seed with a chemical or peptide-associated pesticide prior to planting the seed is also disclosed.02-04-2010
20100029724SCREENING METHOD - The present invention provides a method of screening for a therapeutic drug for diabetes or a nerve system disease, including using ferrochelatase, and a ferrochelatase activator containing a compound represented by the formula:02-04-2010
20110118321CARBAMOYLBENZOTRIAZOLE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.05-19-2011
20110034523CRYSTALLINE FORMS OF RUFINAMIDE - Disclosed is a crystalline form of rufinamide selected from: 02-10-2011
20120041040FUNCTIONALIZED 4- AND 5-VINYL SUBSTITUTED REGIOISOMERS OF 1, 2, 3-TRIAZOLES VIA 1, 3-DIPOLAR CYCLOADDITION AND POLYMERS THEREOF - The present invention provides novel functionalized mixtures 4- and 5-vinyl substituted regioisomers of 1,2,3-triazoles via 1,3-dipolar cycloaddition. Functionalized alkyne moieties with a terminal alcoholic functionality are reacted with functionalized organic moieties with a terminal leaving group and an azide to provide an alcoholic functionalized mixture of 4- and 5-substituted regioisomers of 1,2,3-triazole moieties. The mixture may be converted to a wide variety of useful functionalized mixtures of 4- and 5-vinyl substituted regioisomers of 1,2,3-triazole moieties, which in turn can be converted to a wide variety of useful polymers The novel alcoholic functionalized mixtures of 4- and 5-substituted regioisomers can be separated by chromatography to provide the purified 4- and 5-alcoholic functionalized substituted 1,2,3-triazole moieties. The novel compounds of the invention can be employed in a wide variety of compositions (Formulae (I), (II)); wherein R02-16-2012
20120010254COMPOUNDS AND METHODS FOR TREATMENT OF INFLUENZA - The present invention provides in part a compound of Formula (I) or a pharmaceutically-acceptable salt or stereoisomer thereof: where R01-12-2012
20120022118COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention relates to compounds of structural formula (I):01-26-2012
20120232119METHOD FOR TREATING A KERATOCONJUNCTIVAL DISORDER - A method for treating a keratoconjunctival disorder, wherein the keratoconjunctival disorder comprises at least one disorder selected from the group consisting of a superficial punctate keratopathy, a corneal epithelial defect, corneal erosion, a corneal ulcer, a conjunctival epithelial defect, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis and conjunctivitis, and wherein the method comprises orally administering from 3 mg/kg to 30 mg/kg per day of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof to a patient in need thereof.09-13-2012
20090105313Preventive or therapeutic agent for keratoconjunctival disorder - An object of the present invention is to provide a new medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent prevention and improvement effect in corneal disorder models, and is therefore useful as a preventive or therapeutic agent for a keratoconjunctival disorder such as dry eye, superficial punctate keratopathy, corneal epithelial defects, corneal erosion, corneal ulcer, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, keratitis or conjunctivitis.04-23-2009
20120322837AMIDE COMPOUND AND MEDICINAL USE THEREOF - A compound of formula [I-W]:12-20-2012
20100168188Estrogen Receptor Modulators - The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.07-01-2010
20120149741TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - There are provided compounds of Formula (I) wherein three of A06-14-2012
20110269803AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS - This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII.11-03-2011
20130096165COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.04-18-2013

Patent applications in class Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

Patent applications in all subclasses Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)